Johnson & Johnson (J&J) has announced that its dual-acting IL-23 inhibitor Tremfya (guselkumab) has been approved by the European Commission (EC) to treat adults with ulcerative colitis (UC).

The driving force behind the recent volatility in the stock and bond markets can be boiled down to one specific item: the ...